Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Galena expands patent portfolio for GALE-401
January 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

PORTLAND, Ore.—Galena Biopharma Inc. announced receipt of a Notice of Allowance from the United States Patent and Trademark Office for a patent application for GALE-401 composition of matter, a controlled-release formulation of anagrelide for use in reducing platelet counts in patients with myeloproliferative neoplasms. The claims encompass controlled-release formulations of GALE-401 in a broad range of unit dosage forms, articles of manufacture containing GALE-401 and methods of reducing platelet counts in patients with a variety of diseases by administering GALE-401, and the patent, when issued, expires in 2029.
 
“This composition of matter patent is an important component in the building of our patent family for GALE-401 … Our controlled-release version of anagrelide may offer treatment benefits for patients suffering from MPNs who may not be tolerating the currently available immediate-release version,” said Dr. Mark W. Schwartz, Galena's president and CEO.
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.